[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658022":3},{"organization":4,"outcomesModule":7,"designInfo":40,"detailedDescription":11,"studyPopulation":11,"armGroups":46,"interventions":57,"overallOfficials":65,"centralContacts":69,"locations":77,"responsibleParty":96,"collaborators":11,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":11,"eligibilityCriteria":105,"healthyVolunteers":101,"sex":106,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":11,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":120,"whyStopped":11,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"The University of Texas Health Science Center, Houston","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of participants that demonstrate resolution of throat pain and fever as reported by the participant\u002Fcaregiver",null,"about 14 days after treatment initiation",{"measure":14,"description":11,"timeFrame":12},"Number of participants that do not require additional or alternative antibiotic therapy for Group A Streptococcal (GAS) pharyngitis",[16,19,21,23,26,29,32,35,38],{"measure":17,"description":11,"timeFrame":18},"Number of participants that demonstrate improvement in pain","From baseline to day 14",{"measure":20,"description":11,"timeFrame":18},"Number of participants that demonstrate improvement in fever",{"measure":22,"description":11,"timeFrame":18},"Number of participants that demonstrate improvement in treatment tolerance",{"measure":24,"description":11,"timeFrame":25},"Number of participants that complete the prescribed antibiotic course, assessed by caregiver report","Day 14",{"measure":27,"description":28,"timeFrame":18},"Number of participants that have Antibiotic-Associated Adverse Effects","Occurrence of non-serious, expected effects (e.g., gastrointestinal symptoms, rash), assessed by caregiver report and chart review",{"measure":30,"description":11,"timeFrame":31},"Number of participants that have recurrence of symptomatic GAS pharyngitis requiring additional medical evaluation or treatment.","From the end of study treatment through Day 30",{"measure":33,"description":11,"timeFrame":34},"Number of participants with an emergency department visit, urgent care visit, or unplanned clinic encounter related to pharyngitis symptoms","Within 30 days after completion of study treatment",{"measure":36,"description":11,"timeFrame":37},"Number of school days missed due to pharyngitis-related illness, as reported by the caregiver.","Within 14 days after completion of study treatment",{"measure":39,"description":11,"timeFrame":37},"Number of caregiver workdays missed due to the child's illness",{"allocation":41,"interventionModel":42,"interventionModelDescription":11,"primaryPurpose":43,"observationalModel":11,"timePerspective":11,"maskingInfo":44},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":45,"maskingDescription":11,"whoMasked":11},"NONE",[47,52],{"label":48,"type":49,"description":11,"interventionNames":50},"5 day short course antibiotic treatment","EXPERIMENTAL",[51],"Drug: 5 day short course antibiotic treatment",{"label":53,"type":54,"description":11,"interventionNames":55},"10 day standard of care antibiotic treatment","ACTIVE_COMPARATOR",[56],"Drug: 10 day standard of care antibiotic treatment",[58,62],{"type":59,"name":48,"description":60,"armGroupLabels":61,"otherNames":11},"DRUG","Participants will receive oral penicillin or amoxicillin for 5 days",[48],{"type":59,"name":53,"description":63,"armGroupLabels":64,"otherNames":11},"Participants will receive oral penicillin or amoxicillin for 10 days",[53],[66],{"name":67,"affiliation":5,"role":68},"Guliz Erdem, MD","PRINCIPAL_INVESTIGATOR",[70,74],{"name":67,"role":71,"phone":72,"phoneExt":11,"email":73},"CONTACT","(713) 500-5806","Guliz.Erdem@uth.tmc.edu",{"name":75,"role":71,"phone":72,"phoneExt":11,"email":76},"Gabriela Del Bianco","Gabriela.Del.Bianco@uth.tmc.edu",[78],{"facility":79,"status":11,"city":80,"state":81,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":90,"contacts":91},"The University of Texas Health Science Center at Houston","Houston","Texas","77030","United States","US",{"type":86,"coordinates":87},"Point",[88,89],-95.36327,29.76328,{"lat":89,"lon":88},[92,94],{"name":67,"role":71,"phone":93,"phoneExt":11,"email":73},"713-500-5806",{"name":95,"role":71,"phone":72,"phoneExt":11,"email":76},"Gabriela Paula Del Bianco",{"type":68,"investigatorFullName":97,"investigatorTitle":98,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Guliz Erdem","Professor","100658022","phase-4-short-versus-standard-amoxicillin-for-pediatric-strep-throat-100658022",false,"NCT07845812","Short Versus Standard Amoxicillin for Pediatric Strep Throat","Short vs Standard Amoxicillin for Pediatric Strep Throat: A Patient-Centered Pragmatic Trial","Inclusion Criteria:\n\n* confirmed Group A streptococcal (GAS) pharyngitis, defined by a positive rapid antigen detection test\n* Receiving care at either the University of Texas Pediatrics General Clinic or the Memorial Hermann Emergency Department\n* Written informed consent obtained from a parent or legal guardian, with assent from the child when developmentally appropriate and required by institutional policy.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to penicillin, amoxicillin, or other beta-lactam antibiotics\n* Severe or complicated illness requiring hospitalization at presentation.\n* History of acute rheumatic fever, post-streptococcal glomerulonephritis, or other conditions for which prolonged antibiotic therapy is specifically indicated.\n* Immunocompromised state, including but not limited to: Active malignancy receiving chemotherapy, Solid-organ or hematopoietic stem cell transplant, Chronic systemic immunosuppressive therapy\n* Antibiotic use with activity against Group A Streptococcus within the preceding 7 days.\n* Inability to take oral medications or anticipated inability to complete outpatient therapy.","ALL","3 Years","18 Years",{"count":110,"type":111},1500,"ESTIMATED","INTERVENTIONAL",[114],"PHASE4","The purpose of this study is to compare 5-day vs 10-day amoxicillin for strep throat in children.",[117],"Group A Streptococcal (GAS) Pharyngitis",[119],"antibiotics","NOT_YET_RECRUITING","2026-09-21",{"date":123,"type":124},"2026-09-29","ACTUAL",{"date":126,"type":111},"2026-09-28",{"date":128,"type":111},"2029-09-28",{"name":5,"class":6},1]